 NEW YORK--BUSINESS WIRE--A group of long-time stockholders the Nominating Stockholders or the Group of CytoDyn Inc. CYDY or the Company OTC: CYDY that has nominated five highly experienced director candidates to serve on the Companys Board of Directors today announced its comprehensive strategic plan to obtain cancer therapy approval for Leronlimab. If implemented, the Group believes this plan would begin to generate much-needed revenue for CYDY and position the Company to earn 